Gatehouse Bio, a pioneer in next-generation therapeutics, is collaborating with AstraZeneca, a global science-led biopharmaceutical company, to explore the identification of new targets for respiratory and cardiovascular diseases using Gatehouse Bio’s Artificial Intelligence (AI)-powered platform.
IONTAS, a leader in the discovery and optimisation of fully human antibodies, today announced it has entered into a collaboration agreement with Adaptate Biotherapeutics, developers of antibody-based therapeutics for modulation of gamma delta T-cells.
Japan-based Astellas Pharma has agreed to acquire AAV-based genetic medicines company Audentes Therapeutics for a total equity value of around $3bn.
LUNAC Therapeutics (LUNAC), a UK based drug discovery company focused on the identification and development of advanced anticoagulants with minimal bleeding risk, announced that, along with the Medicines Discovery Catapult and the University of Leeds, it has been awarded £3.14M funding under Innovate UK’s Biomedical Catalyst programme.
WuXi ATU Co, a subsidiary of WuXi AppTec, and GeneMedicine - a South Korea-based gene therapy biotechnology company, have formed a strategic partnership for the development and manufacturing of oncolytic virus products. Under the terms of the collaboration, WuXi ATU will provide overall process development, manufacturing and Investigational New Drug (IND) filing services for GeneMedicine's oncolytic virus products.
Lonza and DiNAQOR AG, a global gene therapy platform company, announced a strategic collaboration to advance DiNAQOR's preclinical programs for the treatment of cardiac myosin-binding protein-C (MYBPC3) cardiomyopathies, a genetic condition that can result in heart failure.
Ferring Pharmaceuticals and Blackstone Life Sciences will make a joint investment of more than $570m in an investigational gene therapy called nadofaragene firadenovec (rAd-IFN/Syn3) for bladder cancer patients.
CARB-X is awarding VenatoRx Pharmaceuticals, (Malvern, Pennsylvania, USA) up to US$4.1 million in non-dilutive funding, with the possibility of up to an additional US$8.9 million if certain project milestones are met, to develop a new class of oral antibiotics to treat infections caused by multi-drug-resistant (MDR) Neisseria gonorrhoeae.
Novartis has agreed to acquire The Medicines Company for about $9.7bn to add inclisiran, an investigational cholesterol-lowering drug, to its cardiovascular portfolio.
Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, and MaxCyte, a global cell-based therapies and life sciences company, today announced a clinical and commercial license agreement under which Vor will use MaxCyte’s Flow Electroporation technology to produce eHSCs and initiate Investigational New Drug (IND)-enabling studies to accelerate its progress towards the clinic.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.